EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access

Effect of Eplerenone Treatment in Patients with Central Serous Retinopathy: A Double-Blind Randomized Clinical Trial

Mohammadreza Akhlaghi, Alireza Dehghani, Farzan Kianersi, Mohammad Reza Khalili, Mohammad Tohidi, Hamidreza Jahanbani-Ardakani

Journal of Current Ophthalmology · 2024-01 · 36 (1) · 61-65

DOI: 10.4103/joco.joco_13_22 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Current Ophthalmology, online erschienen am 16.10.2024. Verfasst von Mohammadreza Akhlaghi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Isfahan Eye Research Center, Department of Ophthalmology, Isfahan University of Medical Sciences, Isfahan, Iran. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

To evaluate the efficacy of eplerenone in central serous chorioretinopathy (CSCR) patients in a clinical trial design.

Methods

In this double-blind clinical trial, naive acute. CSCR patients were divided into two groups: treatment with eplerenone 25 mg daily in the 1 st week followed by 50 mg for the next 3 weeks and placebo group. Best-corrected visual acuity (BCVA), central macular thickness (CMT), macular volume (MV), and choroidal thickness (CT) were measured before and after 1 month of the intervention using the optical coherence tomography technique.

Results

Thirty-one CSCR (male: 23, female: 8) and 25 CSCR patients (male: 18, female: 7) with the mean age of 35.65 ± 5.94 and 37.08 ± 6.41 years were recruited and divided randomly into treatment and placebo groups, respectively. BCVA improved significantly in the treatment group (from 0.28 ± 0.26 to 0.11 ± 0.14, P = 0.002) compared with the placebo group (from 0.31 ± 0.26 to 0.21 ± 0.14, P = 0.052). Although CT, CMT, and MV improved significantly in each group, there were no significant differences between the groups.

Conclusion

In this study, we found favorable short-term clinical effects of eplerenone in acute CSCR patients, showing the pivotal role of mineralocorticoid receptors in the retina.

Schlagwörter

Stichwörter der Autor:innen

Best-corrected visual acuityCentral macular thicknessCentral serous chorioretinopathyChoroidal thicknessEplerenone

Autor:innen und Institutionen

  • Isfahan Eye Research Center, Department of Ophthalmology, Isfahan University of Medical Sciences, Isfahan, Iran.
  • Department of Ophthalmology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.

Zitieren

APA

Akhlaghi, M., Dehghani, A., Kianersi, F., Khalili, M. R., Tohidi, M., & Jahanbani-Ardakani, H. (2024). Effect of Eplerenone Treatment in Patients with Central Serous Retinopathy: A Double-Blind Randomized Clinical Trial. Journal of Current Ophthalmology, 36(1), 61-65. https://doi.org/10.4103/joco.joco_13_22

Vancouver

Akhlaghi M, Dehghani A, Kianersi F, Khalili MR, Tohidi M, Jahanbani-Ardakani H. Effect of Eplerenone Treatment in Patients with Central Serous Retinopathy: A Double-Blind Randomized Clinical Trial. Journal of Current Ophthalmology. 2024;36(1):61-65. doi:10.4103/joco.joco_13_22

BibTeX
@article{Akhlaghi2024,
  author = {Akhlaghi, Mohammadreza and Dehghani, Alireza and Kianersi, Farzan and Khalili, Mohammad Reza and Tohidi, Mohammad and Jahanbani-Ardakani, Hamidreza},
  title = {Effect of Eplerenone Treatment in Patients with Central Serous Retinopathy: A Double-Blind Randomized Clinical Trial},
  journal = {Journal of Current Ophthalmology},
  year = {2024},
  volume = {36},
  number = {1},
  pages = {61--65},
  doi = {10.4103/joco.joco_13_22}
}
Kostenlos starten →